Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Date:12/9/2008

Dr. Paul Richardson presents combined results from a Phase 1/2 study of perifosine in combination with bortezomib (+/- dexamethasone) in multiple myeloma patients relapsed from or refractory to bortezomib

NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. The data was presented earlier today at the 50th annual meeting of the American Society of Hematology in an oral presentation by Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI).

The study entitled "A Multicenter Phase 1/2 Study Evaluating the Safety and Efficacy of Perifosine (KRX-0401) + Bortezomib (VELCADE(R)) in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma Who Were Previously Treated with Bortezomib," has completed enrollment with 84 patients, of which 24 remain on active treatment. In his presentation, Dr. Richardson presented results from the study as follows:

Trial Summary:

Eighty-four patients were enrolled in a combined Phase 1/2 study (18 patients in the Phase I component and 66 patients in the Phase II component). Median prior lines of therapy was 5 (range 1 - 13), including; 100% of patients had been treated with bortezomib (50% of the patients were previously treated with at least two bortezomib-based therapies and 81% were previously treated with bortezomib plus dexamethasone); 98% of patients were previously treated with dexamethasone; 98% of patients were previously treated with lenalidomide (Revlimid(R)) and/or thalidomide (Thalomid(R)); and 57% of patients had prior stem cell transplant. No unexpected adve
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... CHICAGO, Dec. 14 Sword Diagnostics, Inc. ... Patent Office (USPTO) has issued patent number ... Biological Organisms using Raman Scattering" to the company. ... on improved sensitivity. ,, "The issuance of ... move forward with our continued development and commercialization," ...
(Date:12/14/2009)... -- Gibraltar Associates, a leading public affairs ... communications and issues management, today announced that ... Corporation (Nasdaq: PSID ) to serve ... record. Gibraltar Associates will conduct media relations ... Company on its public relations programs. ,, ...
(Date:12/14/2009)... /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC ... received a complete response letter from the U.S. ... New Drug Application ("NDA") for Onrigin(TM) (laromustine) injection ... that the FDA cannot approve the Company,s NDA ... address remaining issues. ,, Alan Kessman, Chief Executive ...
Breaking Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3New Stress Busting Drink Tranquila 28TM 29 Quenches Jangled Nerves 56354 1New Stress Busting Drink Tranquila 28TM 29 Quenches Jangled Nerves 56354 2New Stress Busting Drink Tranquila 28TM 29 Quenches Jangled Nerves 56354 3Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 13883 1Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 13883 2Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 13883 3Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 13883 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 13881 1Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 13881 2Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 13881 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 13881 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 13881 5
... WALTHAM, Mass., Nov. 6 Inverness Medical,Innovations, Inc. ... marketer of rapid,diagnostic products for the consumer and ... World Markets, 18th Annual Healthcare,Conference on November 7, ... Jon Russell, Vice President of Finance, will attend. ...
... Clinical Evaluation Anticoagulant Inhibits Clotting Factor IXa; ... Reverses Anticoagulant Effect, ORLANDO, Fla., Nov. 6 ... Phase Ib dose escalation,studies of the Company,s REG1 Anticoagulation ... anticoagulant, RB006,and its matched antidote, RB007, which binds to ...
Other Medicine Technology:Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions 2Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions 3
(Date:12/14/2009)... ,, NEW YORK, Dec. 14 /PRNewswire-USNewswire/ -- ... -- the largest survey on teen drug abuse tracking ... that teens, intentional abuse of prescription (Rx) and over-the-counter ... with an alarming number of young people abusing medicines ... Teen Abuse of Medication Continues to Be a ...
(Date:12/14/2009)... Dec. 14 The Hemophilia Federation of ... labor issues involving the Teamsters Local 929 and ... The national blood system depends on skilled workers ... blood is distilled into products such as clotting ... Willebrand disease. ,, The Division of Blood ...
(Date:12/14/2009)... treated, hadn,t spread, study finds , , MONDAY, Dec. 14 ... of death in male colon cancer survivors, researchers report. ... 668 men who,d been treated for stage I, stage ... spread (nonmetastatic cancer). Every two years, the men were ... and disease diagnoses, as well as their physical activity. ...
(Date:12/14/2009)... offer some protection, study finds, , , MONDAY, Dec. 14 ... can,t start their morning without a cup or two ... risk of developing type 2 diabetes. , That,s ... the more coffee you drink, the lower your risk ... a 7 percent reduction in the risk of diabetes, ...
(Date:12/14/2009)... disorders are underdiagnosed, poorly treated and highly stigmatized, ... Eugene H. Rubin, M.D., Ph.D. So these Washington ... those problems. , In "Demystifying Psychiatry," Zorumski and ... experience treating psychiatric patients and helping patient families, ... illness and treatment result from a lack of ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:HFA Voices Blood Safety Concerns 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Coffee, Tea Might Stave Off Diabetes 2Health News:Coffee, Tea Might Stave Off Diabetes 3Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3
... SectorWatch.biz announces the,availability of MarketStats for Healthier ... MarketStats offers a perspective on the,aforementioned equities and ... opinions on the subject and sector creating a ... MarketStats by visiting: http://www.SectorWatch.biz ,-- a division ...
... The Board of,Directors of Rural/Metro Corporation (Nasdaq: RURL ... fire protection services,announced today that Mr. Conrad A. Conrad ... joined the Rural/Metro Board of Directors in October 2005,and ... and Compensation committees.,He succeeds Mr. Cor Clement, who announced ...
... ... Lake City, UT (PRWEB) July 10, 2008 – Two Little Hands ... and hit public television show designed to teach babies , toddlers ... pleased to announce the release of two new DVDs completing Series Two ...
... Park Avenue Laser Vision (PALV) Center recently appeared on Fox ... guest to discuss the issue of offering his patients discounts ... video sharing site, YouTube. Dr. Chynn explains on the ... to reach people in their 20s, 30s, and 40s who ...
... and soccer players who have had a previous concussion ... of concussion, new research released today at the 2008 ... the JW Marriott Orlando Grande Lakes shows. The study ... for significant differences in test results following the injury. ...
... SmoothToe, the only brand,of diabetic socks available anywhere ... well as a Five Year Extended Warranty, has new ... ( http://www.SmoothToe-Socks.com ) is pleased,to announce its April 1st ... their introduction to the UK via the website:, http://www.SmoothToe.co.uk ...
Other Medicine News:Health News:SectorWatch.biz Issues MarketStats on Healthy Living Companies UKMA, LULU, GAIA, NTRI, and WTW 2Health News:Conrad A. Conrad Elected Chairman of the Board for Rural/Metro Corporation 2Health News:Two Little Hands Productions Completes the Second Series of Signing Time With Two New DVDs 2Health News:Dr. Emil Chynn Featured on FOX News (WNYW-TV) Park Avenue Laser Vision Center Recognized for Creative Internet Marketing 2Health News:Dr. Emil Chynn Featured on FOX News (WNYW-TV) Park Avenue Laser Vision Center Recognized for Creative Internet Marketing 3Health News:Men and women with history of concussion mend differently, study finds 2Health News:SmoothToe Diabetic Socks Acquired by Lifestyle Medical Group 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: